Onconetix and Realbotix amend share exchange terms, push deadline to March 2027
The amendment adjusts ownership terms tied to a net cash threshold and extends the deal's closing deadline by several months.
SEC filing
3 stories
The amendment adjusts ownership terms tied to a net cash threshold and extends the deal's closing deadline by several months.
SEC filing
The move completes a previously authorized split program, cutting share count to about 589,000 shares outstanding.
SEC filing
The company appointed R. Duane Clark II and James Sapirstein to its board on September 8, 2026, as Ebstrocel nears potential commercialization.
SEC filing